|Dr. Richard M. Glickman L.L.D. (Hon)||Founder, Chairman & CEO||88.42k||N/A||59|
|Mr. Michael R. Martin||Co-Founder and Chief Operating Officer||280.66k||N/A||N/A|
|Mr. Dennis Bourgeault C.A.||Chief Financial Officer and Sec.||261.3k||N/A||N/A|
|Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C)||Exec. VP of Corp. Devel.||257.46k||N/A||N/A|
|Dr. Neil Solomons M.D.||Chief Medical Officer||334.8k||N/A||N/A|
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc. and 3SBio, Inc. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Aurinia Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.